Keyword → CI

Earlier

Tesla Q2 2026 Earnings Wednesday Pits Record 480,126 Deliveries Against Revenue Estimated Below $26.4B — Margins and Cybercab Timeline Are the Real Test

Jul 21, 2026

neutral

Tesla Q2 2026 Earnings Wednesday Pits Record 480,126 Deliveries Against Revenue Estimated Below $26.4B — Margins and Cybercab Timeline Are the Real Test

Tesla reports Q2 2026 earnings after the bell Wednesday, July 22, with record deliveries of 480,126 vehicles — up 25% year-over-year and 18% above consensus — already public. The paradox is that revenue is expected near $26.4 billion, potentially below last year's comparable quarter, as aggressive pricing erodes per-vehicle economics. Investors will focus on automotive gross margin, the Cybercab production timeline, and whether $25 billion in 2026 capital expenditure is generating credible near-term returns.

Trump Alleges China Stole 220 Million US Voter Files in Primetime Address — US-China Tensions Spike Ahead of Midterms

Jul 17, 2026

negative

Trump Alleges China Stole 220 Million US Voter Files in Primetime Address — US-China Tensions Spike Ahead of Midterms

President Trump delivered a primetime address Thursday alleging China illicitly acquired 220 million US voter files — the largest election data compromise in history — while revealing declassified intelligence on Chinese interference operations. Beijing denied the claims. The speech, delivered months before the 2026 midterm elections, renews US-China tensions and could accelerate restrictions on Chinese technology companies. US-listed Chinese ADRs and cybersecurity stocks are the most direct market plays.

UnitedHealth Q2 2026 EPS Hits $6.38, Beats by $1.46 — Full-Year Guidance Raised to $19.50–$20.00 as Medical Ratio Falls to 86.7%

Jul 16, 2026

positive

UnitedHealth Q2 2026 EPS Hits $6.38, Beats by $1.46 — Full-Year Guidance Raised to $19.50–$20.00 as Medical Ratio Falls to 86.7%

UnitedHealth Group reported Q2 2026 adjusted EPS of $6.38, crushing the $4.90 consensus by $1.46, as revenue reached $112.03 billion versus $110.85 billion expected. The medical benefit ratio improved sharply to 86.7% from 89.4% a year ago. Full-year adjusted EPS guidance was raised to $19.50–$20.00, well above the prior outlook of greater than $18.25. Cash flow guidance was lifted to $24 billion. Shares jumped roughly 7% premarket, outperforming a broadly declining tape.

Intel Surges 70% in 2026 as Terafab Partnership and Google AI Deal Cement Semiconductor Comeback

Apr 13, 2026

positive

Intel Surges 70% in 2026 as Terafab Partnership and Google AI Deal Cement Semiconductor Comeback

Intel has emerged as one of the S&P 500's most dramatic turnaround stories in 2026, with its stock gaining approximately 70% year-to-date after confirming its role in Elon Musk's Terafab AI chip megafab initiative and deepening a strategic AI partnership with Google Cloud. Analysts have raised price targets as high as $92, though the stock currently trades at a stretched forward P/E of around 94 times, reflecting high expectations for future earnings growth.

Meta Locks In $21 Billion CoreWeave AI Deal, Bringing Total Commitment to $35 Billion Through 2032

Apr 10, 2026

positive

Meta Locks In $21 Billion CoreWeave AI Deal, Bringing Total Commitment to $35 Billion Through 2032

CoreWeave announced Thursday an expanded $21 billion long-term agreement to supply AI cloud computing capacity to Meta Platforms through December 2032, raising the two companies' combined deal value to $35 billion and including early commercial deployments of Nvidia's next-generation Vera Rubin GPU platform — cementing Meta's position as one of CoreWeave's largest customers and reinforcing the accelerating race for AI infrastructure.

What we cover

STKMRKT publishes daily stock market news covering earnings reports, pre-market movers, Fed policy, macroeconomic data releases, sector trends, and cryptocurrency updates. Every article is written for active traders and long-term investors who need fast, actionable context — not noise.

Page 1 of 8